Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesTransplantHealth Plan Islet Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentHealth Plan of the Upper Ohio ValleyPolicy 19215698

    Pancreatic Islet Cell Transplantation

    Customize your policy alerts

    Sign up for healthplanofupperohiovalley Policy 19215698 alerts

    Get alerted when Policy 19215698 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and coding for allogeneic pancreatic islet cellular therapy and autologous pancreatic islet transplantation, including excluded or investigational islet-related services.

    Policy Summary
    PayerHealth Plan of the Upper Ohio Valley
    PolicyPancreatic Islet Cell Transplantation
    Policy CodePolicy 19215698
    Change TypeNew policy
    Effective DateJan 24, 2026
    Next Review DateN/A
    Key ActionDocument the applicable medical necessity criteria in the medical record before submitting a request.
    SourceLink
    POLICY UPDATE CHANGES

    A new policy establishes coverage criteria for allogeneic pancreatic islet cellular therapy and autologous islet transplantation.

    18+Minimum age for covered allogeneic transplantation
    3Maximum covered allogeneic infusions/transplants
    2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered transplantation pathways
    4Excluded or non-covered service categories
    6Coding categories

    Covered and Non-Covered Services

    Allogeneic Pancreatic Islet Cellular Therapy

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Member is 18 years of age or older.
    • Member has type 1 diabetes and is unable to approach target hemoglobin A1C (HbA1c) due to current repeated episodes of severe hypoglycemia despite intensive diabetes management and education.
    • Lantidra will be used in conjunction with concomitant immunosuppression therapy, such as mycophenolate mofetil, sirolimus, or tacrolimus.
    • Member has not received a renal transplant.
    • Administration has not exceeded a maximum of 3 infusions (transplants).

      There is no data regarding the effectiveness or safety of more than 3 infusions.

    Repeat Lantidra Infusion

    A Lantidra infusion (transplant) may be repeated when ALL of the following criteria are met:

    ALL of the following

    • Member meets all initial approval criteria.
    • At least ONE of the following

      • Member has not achieved independence from exogenous insulin within one year of the infusion.
      • Member lost independence from exogenous insulin after a previous infusion, and one year has elapsed since the loss of independence.

    The following services are excluded and not covered: bioartificial pancreas device (BAP); ex-situ machine pancreas perfusion, in hypothermic or normothermic settings, for pancreas transplantation; and pancreatic islet xenotransplantation.

    Islet transplantation is not covered in situations other than those specifically listed as covered in this Coverage Policy, including when the primary indication is increased longevity or lifestyle-related, such as a desire to no longer take insulin.

    Pancreatic islet cell allogeneic transplantation is considered investigational and not medically necessary when the allogeneic coverage criteria are not met and for all other indications.

    Autologous pancreatic islet cell transplantation is considered investigational and not medically necessary when the covered medical-necessity criteria are not met and for all other indications.

    Autologous pancreas islet transplantation may be considered medically necessary as an adjunct to a total or near-total pancreatectomy in individuals with severe chronic pancreatitis that cannot be managed by other treatments.

    The policy states that allogeneic islet cell transplant using an FDA-approved cellular therapy product, donislecel-jujn (Lantidra), is considered investigational for the treatment of type 1 diabetes.

    Per CMS, Lantidra is used only in the inpatient setting and does not have an individual HCPCS code. If needed, it should be billed under J3590 (unclassified biologics) or C9399 (unclassified drugs or biologicals).

    Coding and Billing Guidance

    Islet cell transplant CPT codesCPT
    0584TIslet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; percutaneous.
    0585TIslet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; laparoscopic.
    0586TIslet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; open.
    Islet cell transplant HCPCS G codesHCPCS
    G0341Percutaneous islet cell transplant, includes portal vein catheterization and infusion.
    G0342Laparoscopy for islet cell transplant, includes portal vein catheterization and infusion.
    G0343Laparotomy for islet cell transplant, includes portal vein catheterization and infusion.
    Allogeneic islet cell transplantHCPCS
    S2102Islet cell tissue transplant from pancreas; allogeneic.
    Lantidra billingHCPCS
    No Specific codeDonislecel-jujn (Lantidra; CellTrans Inc).
    J3590Unclassified biologics.
    C9399Unclassified drugs or biologicals.
    Allogeneic treatment limit
    Maximum allogeneic infusions/transplantsAdministration has not exceeded a maximum of 3 infusions (transplants).
    Repeat treatment limitThere is no data regarding effectiveness or safety for more than 3 infusions.
    Repeat infusion timing
    Repeat infusion windowWithin one year of the prior infusion, or within one year after losing independence from exogenous insulin after a previous infusion.
    Additional requirementThe member must meet all initial approval criteria and must not have achieved independence from exogenous insulin within the applicable period.

    Documentation and Coverage Risk

    Documentation Required

    Medical Necessity Documentation Required

    Ensure the medical record documents how the applicable medical-necessity criteria are met. Records are subject to audit by THP at any time under the terms of the provider agreement.

    • Document the clinical indications, eligibility factors, treatment history, and applicable coverage criteria supporting the request.
    • Retain records for post-payment review and audit.
    Note

    Verify Eligibility and Benefits

    Providers are encouraged to verify member eligibility and benefits before submitting a request for pancreatic islet cell transplantation, because some plans limit certain types of services.

    • Confirm eligibility and benefits before requesting transplantation services.

    Clinical Background

    Pancreatic islet transplantation transfers insulin-producing islet cells to help regulate blood glucose. Allogeneic transplantation uses cells from a genetically non-identical human donor, whereas autologous transplantation uses the member’s own pancreatic islet cells, typically infused into the liver’s portal vein after pancreatectomy. This policy addresses allogeneic therapy for selected adults with type 1 diabetes and severe hypoglycemia, and autologous transplantation as an adjunct to pancreatectomy for severe chronic pancreatitis that cannot be managed by other treatments.

    Key Terms

    Definition
    AllogeneicTaken from different individuals of the same species; in this policy, human cadaver cells.
    Definition
    Allogeneic transplantationTransplantation of islet cells from a genetically non-identical donor of the same species; also known as allogeneic pancreatic islet cellular therapy.
    Definition
    AutologousCells or tissues obtained from the same individual.
    Definition

    Candidate Eligibility

    Allogeneic candidate criteria

    Covered allogeneic candidates must meet all of the following criteria:

    • Member is an adult, 18 years of age or older.Age >=18
    • Member has type 1 diabetes.
    • Member is unable to approach target hemoglobin A1C (HbA1c) because of current repeated episodes of severe hypoglycemia despite intensive diabetes management and education.
    • Lantidra will be used in conjunction with concomitant immunosuppression therapy, such as mycophenolate mofetil, sirolimus, or tacrolimus.

    Contraindications and Exclusions

    A prior renal transplant excludes the member from the stated allogeneic pancreatic islet transplantation coverage criteria.

    Policy Summary
    PayerHealth Plan of the Upper Ohio Valley
    PolicyPancreatic Islet Cell Transplantation
    Policy CodePolicy 19215698
    Change TypeNew policy
    Effective DateJan 24, 2026
    Next Review DateN/A
    Key ActionDocument the applicable medical necessity criteria in the medical record before submitting a request.
    SourceLink
    On This Page
    Covered and Non-Covered ServicesCoding and Billing GuidanceDocumentation and Coverage RiskClinical BackgroundKey TermsCandidate EligibilityContraindications and Exclusions
    Denial Risk

    Allogeneic Criteria Not Met

    Allogeneic pancreatic islet transplantation is investigational and not medically necessary when the applicable coverage criteria are not met or for any other indication.

    • Member is at least 18 years old.
    • Member has type 1 diabetes and cannot reach target HbA1c because of repeated severe hypoglycemia despite intensive diabetes management and education.
    • Lantidra is used with concomitant immunosuppression.
    • Member has not received a renal transplant.
    • Administration does not exceed three infusions (transplants).
    Denial Risk

    Autologous Criteria Not Met

    Autologous pancreatic islet cell transplantation is investigational and not medically necessary when the applicable coverage criteria are not met or for any other indication.

    • Coverage is limited to use as an adjunct to total or near-total pancreatectomy in an individual with severe chronic pancreatitis that cannot be managed by other treatments.
    Denial Risk

    Explicitly Excluded Services

    The following services are excluded and non-covered. Claims for these services, or for islet transplantation in situations other than those specifically listed as covered, may be denied.

    • Bioartificial pancreas devices (BAP).
    • Ex-situ machine pancreas perfusion for pancreas transplantation, including hypothermic or normothermic settings.
    • Pancreatic islet xenotransplantation.
    • Islet transplantation in all other situations not listed as covered in the Coverage Policy.
    Denial Risk

    Lifestyle or Longevity Indication

    Islet transplantation is non-covered when the primary indication is increased longevity or a lifestyle preference, such as wanting to stop taking insulin. Requests based on these indications are subject to denial.

    • Increased longevity.
    • Lifestyle-related indications, including a desire to no longer take insulin.
    Bioartificial device (BAP)
    A long-term-use device combining living insulin-secreting cells or islets with a synthetic membrane or capsule to create a hybrid therapy intended to regulate blood glucose.
    Definition
    Ex-situ machine pancreasA short-term process for evaluating or treating a donor pancreas outside the body by perfusing it with a warm, oxygenated solution before transplantation.
    Definition
    Islet cell auto-transplantationInfusion of a patient's own pancreatic islet cells into the portal vein of the liver.
    Definition
    Islet cellA pancreatic cell that produces hormones such as insulin and glucagon, which are secreted into the bloodstream to help control blood glucose.
    Member has not received a renal transplant.
  1. The member will not receive more than 3 total infusions (transplants).Maximum 3 infusions/transplants
  2. Autologous candidate criteria

    Autologous candidates may be considered medically necessary when all of the following are met:

    • The individual has severe chronic pancreatitis that cannot be managed by other treatments.
    • Autologous pancreatic islet transplantation is performed as an adjunct to a total or near-total pancreatectomy.Total or near-total pancreatectomy